These inhibitors, in conjunction with ET, are currently utilized as a rescue strategy for advanced BC (ABC) (9–11) and as intensive adjuvant therapy for early breast cancer (EBC) (12) in HR+ and HER2 negative populations. The gene discussed is ERBB2; the disease is breast carcinoma.